Clinical applications of pharmacologic therapies for spinal cord injury.
We review the evidence supporting the role of glucocorticosteroids, trilazad, and GM1 ganglioside in spinal cord injury and provide our critique of the published studies, along with our recommendations for pharmacologic therapy for this complex and difficult problem.
Zeidman
S M
SM
Department of Surgery, Walter Reed Army Medical Center, USA.
Ling
G S
GS
Ducker
T B
TB
Ellenbogen
R G
RG
D015761:4-Aminopyridine / Q000627:therapeutic use; D000818:Animals; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004353:Drug Evaluation, Preclinical; D016166:Free Radical Scavengers / Q000627:therapeutic use; D005677:G(M1) Ganglioside / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008775:Methylprednisolone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D009270:Naloxone / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D011281:Pregnatrienes / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013119:Spinal Cord Injuries / Q000188:drug therapy*; D016896:Treatment Outcome
D002121:Calcium Channel Blockers; D016166:Free Radical Scavengers; D005938:Glucocorticoids; D018696:Neuroprotective Agents; D011281:Pregnatrienes; C074965:U 74389F; D009270:Naloxone; D005677:G(M1) Ganglioside; D015761:4-Aminopyridine; D008775:Methylprednisolone